{
    "clinical_study": {
        "@rank": "109436", 
        "arm_group": [
            {
                "arm_group_label": "lipoic acid and omega-3 fatty acids", 
                "arm_group_type": "Experimental", 
                "description": "lipoic acid and omega-3 fatty acids"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo oil and placebo lipoic acid"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary aim is to collect data to determine the correct effect size on the primary\n      outcome to aid in the design of a larger study: The primary outcome is to determine if\n      lipoic acid and omega-3 fatty acids can improve cognitive function in people with multiple\n      sclerosis that have cognitive dysfunction."
        }, 
        "brief_title": "Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Multiple Sclerosis", 
            "Cognition"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis", 
                "Cognition Disorders"
            ]
        }, 
        "detailed_description": {
            "textblock": "The study is designed as a randomized, double-blind, placebo-controlled pilot trial. The\n      primary aim of the study is to determine if lipoic acid and omega-3 fatty acids can improve\n      cognitive function over 12-weeks in people with multiple sclerosis that have a baseline\n      score of at least two standard deviations below normative values on any one of four\n      cognitive tests that include, Paced Auditory Serial Addition Task (PASAT), Stroop Color-Word\n      Test, California Verbal Learning Test-II (CVLT-II), and Controlled Oral Word Association\n      Test (COWAT).\n\n      The secondary aim is to determine treatment effects on markers of endothelial inflammation,\n      insulin dysregulation, and mitochondrial dysfunction that may be related to cognitive\n      dysfunction by measuring s-ICAM-1 levels, homeostasis model of insulin resistance (HOMA-IR),\n      and MRI phosphorus imaging in a subset of study participants. The study will also measure\n      safety by adverse event reports and laboratory measures; plasma fatty acid levels; serum\n      lipoic acid levels."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  \u2022 A definite diagnosis of MS  with relapsing remitting or secondary progressive\n             course\n\n               -  Age 18 to 65 years, inclusive\n\n               -  A score two or more standard deviations below the mean in one or more of the\n                  following cognitive tests: PASAT, COWAT, CVLT -II, Stroop\n\n               -  Expanded Disability Status Scale (EDSS) 0-7.5, inclusive\n\n               -  Suboptimal omega-3 levels (plasma DHA + EPA < 5.0% of total plasma fatty acids)\n\n               -  If taking MS disease modifying medications, on stable dose for > 6 months\n                  preceding enrollment\n\n               -  Able to read and write English\n\n        Exclusion Criteria:\n\n          -  \u2022 Moderate to severe depression (Beck Depression Inventory score > 19)\n\n               -  Any significant uncontrolled medical problem including diabetes requiring\n                  insulin.\n\n               -  MS relapse within the 30 days before screening\n\n               -  Abnormalities of coagulation or current use of prescription anticoagulants or\n                  antiplatelet agents.  Aspirin and other nonsteroidal anti-inflammatory drugs\n                  (NSAIDs) are not excluded.\n\n               -  Fish intake of one 6 ounce serving > once a week less than 2 months prior to\n                  enrollment\n\n               -  Omega-3 fatty acid supplement intake (e.g. fish oil capsules, cod liver oil)\n                  less than 2 months prior to enrollment\n\n               -  Lipoic Acid supplementation less than 1 month prior to enrollment\n\n               -  Taking systemic corticosteroids, neuroleptics, antiparkinsonian agents, and/or\n                  narcotic analgesics. Low dose sinemet and dopamine agonist taken once a day for\n                  restless leg syndrome is not an exclusion.\n\n               -  Contraindications to MRI, including: subjects with intrathecal pumps,\n                  stimulators, pacemakers, aneurysm clips, non-removable hearing aids, or metal\n                  fragments in the eyes. Other exclusion criteria include the inability to lie\n                  flat on the back for 40 minutes at a time or a self-reported history of\n                  claustrophobia. Subjects with a history of hip replacement and those with\n                  well-documented, verifiable, MRI-safe cardiac stents will not be excluded from\n                  the study.\n\n               -  Epilepsy or history of seizures.\n\n               -  Pregnancy or women not using a reliable form of contraception\n\n               -  Corrected binocular visual acuity worse than 20/50 or more than one error on\n                  binocular color vision testing with the Ishihara Color plates or sustained\n                  nystagmus or diplopia on primary gaze\n\n               -  Inability to complete the neuropsychological test battery at the screening visit\n\n               -  Participation in another intervention study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "53", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02133664", 
            "org_study_id": "PP2190"
        }, 
        "intervention": [
            {
                "arm_group_label": "lipoic acid and omega-3 fatty acids", 
                "description": "alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid", 
                "intervention_name": "Alpha lipoic acid and omega-3 fatty acids", 
                "intervention_type": "Drug", 
                "other_name": [
                    "thiotic acid", 
                    "fish oil", 
                    "fish oil concentrate"
                ]
            }, 
            {
                "arm_group_label": "placebo", 
                "description": "placebo lipoic acid and placebo oil", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug", 
                "other_name": "placebo lipoic acid and placebo oil"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Thioctic Acid"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "multiple sclerosis", 
            "cognition", 
            "clinical trial", 
            "thiotic acid", 
            "Omega-3 fatty acids"
        ], 
        "lastchanged_date": "May 7, 2014", 
        "location": {
            "contact": {
                "email": "thompand@ohsu.edu", 
                "last_name": "Andie Thompson, BA", 
                "phone": "503-494-7240"
            }, 
            "contact_backup": {
                "email": "borgatti@ohsu.edu", 
                "last_name": "Alena Borgatti, BA", 
                "phone": "503-494-7798"
            }, 
            "facility": {
                "address": {
                    "city": "Portland", 
                    "country": "United States", 
                    "state": "Oregon", 
                    "zip": "97239"
                }, 
                "name": "Oregon Health and Science University"
            }, 
            "investigator": {
                "last_name": "Lynne Shinto, ND, MPH", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Lipoic Acid and Omega-3 Fatty Acids for Cognitive Impairment in Multiple Sclerosis", 
        "overall_contact": {
            "email": "thompand@ohsu.edu", 
            "last_name": "Andie Thompson, BA", 
            "phone": "503-494-7240"
        }, 
        "overall_contact_backup": {
            "email": "borgatti@ohsu.edu", 
            "last_name": "Alena Borgatti, BA", 
            "phone": "503-494-7798"
        }, 
        "overall_official": {
            "affiliation": "Oregon Health and Science University", 
            "last_name": "Lynne Shinto, ND, MPH", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Change over 12 weeks in any one of the following cogntivie tests, Paced Auditory Serial Addition Task (PASAT), Stroop Color-Word Test, California Verbal Learning Test-II (CVLT-II), and Controlled Oral Word Association Test (COWAT).", 
            "measure": "Cognitive Test", 
            "safety_issue": "No", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02133664"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Oregon Health and Science University", 
            "investigator_full_name": "Lynne Shinto", 
            "investigator_title": "Associate Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Oregon Health and Science University", 
        "sponsors": {
            "collaborator": {
                "agency": "National Multiple Sclerosis Society", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Oregon Health and Science University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}